Heat Biologics, Inc. to Present at 12th Annual BIO Investor Forum
CHAPEL HILL, NC -- (Marketwired) -- 10/02/13 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will present a company overview at the 12th Annual BIO Investor Forum in San Francisco, CA on Wednesday, October 9, 2013 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern time).
A webcast of Mr. Wolf's remarks will be available live. You can access the webcast at the Company's website: www.heatbio.com.
About Heat Biologics:
Heat Biologics (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel off-the-shelf ImPACT therapeutic vaccines to combat a wide range of cancers. Our proprietary ImPACT Therapy is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat shock protein gp-96 is a chaperone protein found in all human cells. Heat's lead compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer and its second product candidate, HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.
Source: Heat Biologics, Inc
Released October 2, 2013